The ZIKAction Kick-Off Meeting was a success!
Kaposi Sarcoma risk in HIV-infected children and adolescents on combination antiretroviral therapy from Eastern Africa, Southern Africa, Europe and Asia.
PENTA Foundation coordinated ZIKAction consortium
First patient enrolled in ODYSSEY study
First patient enrolled in PED-MERMAIDS study
Editorial Overview: Virus–vector interactions
Is pregnancy a barrier to the proposed lower dose of efavirenz?
Timing of the postpartum curve in pharmacokinetic studies in pregnancy should not be too early
A Comparison of the Pharmacokinetics of Efavirenz During Pregnancy and Postpartum
Etravirine Pharmacokinetics in HIV-Infected Pregnant Women
Substantially lowered dolutegravir exposure in a treatment-experienced perinatally HIV-1-infected pregnant woman
The 1st patient was screened in SMILE in Spain
BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial
The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women
High prevalence of herpes simplex virus (HSV)- type 2 co-infection among HIVpositive women in Ukraine, but no increased HIV mother-to-child transmission risk
Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption
First reported use of elvitegravir and cobicistat during pregnancy